Pneumococcal conjugate second or third-dose vaccines (PCVc) in India
India: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 97.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in India, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
India recorded 97.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
That represents a change of up 2.1% on the previous year and up 361.9% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in India peaked at 97.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places India 17th out of 194 countries with data for 2025, putting it in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in India, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 6.0% | — |
| 2019 | 15.0% | +150.0% |
| 2020 | 21.0% | +40.0% |
| 2021 | 25.0% | +19.0% |
| 2022 | 66.0% | +164.0% |
| 2023 | 83.0% | +25.8% |
| 2024 | 95.0% | +14.5% |
| 2025 | 97.0% | +2.1% |
India compared with similar countries
- India's 97.0% is above the median for lower middle income countries, which is 84.0%, 1.2× the median. (47 countries reporting)
- India's 97.0% is above the median for South Asia, which is 94.0%, 1.0× the median. (6 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 2.1% | 0.0% | 15.0% | 10 |
| 2020s | 64.5% | 21.0% | 97.0% | 6 |
Countries ranked near India
More health data for India
- Un projection of annual infant deaths, annual growth rate -2.12 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4372 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,332 deaths per 1,000 people (2090)
- Number of infants who die before age 1 44,822 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 38 (2025)
- Population ages 00-04, female, annual growth rate -0.3809 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0372 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.5922 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in India?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in India was 97.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in India?
- The highest recorded value was 97.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in India?
- The lowest recorded value was 0.0% in 2008.
- How does India rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- India ranks 17th out of 194 countries with data for 2025.
- Where does this India data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).